Cullinan Therapeutics (CGEM) Current Leases (2022 - 2026)

Cullinan Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $725000.0 for Q1 2026.

• On a quarterly basis, Current Leases fell 46.18% year-over-year to $725000.0 in Q1 2026; TTM through Mar 2026 was $725000.0, a 46.18% decrease from a year earlier, with the FY2025 full-year figure at $780000.0, down 40.09% from the prior year.
• Current Leases declined to $725000.0 in Q1 2026 per CGEM's latest filing, from $780000.0 in the prior quarter.
• Across five years, Current Leases topped out at $1.7 million in Q2 2023 and bottomed at $519000.0 in Q1 2022.
• The 5-year median for Current Leases is $1.3 million (2024), against an average of $1.2 million.
• Across the five-year window, Current Leases soared 209.94% in 2023 and slumped 46.18% in 2026, its largest moves.
• Year by year, Current Leases stood at $1.4 million in 2022, then advanced by 1.34% to $1.4 million in 2023, then declined by 9.58% to $1.3 million in 2024, then slumped by 40.09% to $780000.0 in 2025, then declined by 7.05% to $725000.0 in 2026.
• Per Business Quant, the three latest CGEM Current Leases figures stand at $725000.0 (Q1 2026), $780000.0 (Q4 2025), and $1.2 million (Q3 2025).